Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02762032 · ClinicalTrials.gov registry record · Phase 1
Natreon Healthy Skin Study - PrimaVie Supplement
A Phase 1 study, sponsored by Ohio State University.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT02762032 is a Phase 1 study that has completed, run by Ohio State University. The registered enrollment target is 45 participants.
The verdict
NCT02762032, a Phase 1 study, has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
This study will demonstrate the ability of the oral supplement, PrimaVie® to improve skin microperfusion, hydration, elasticity and barrier function. 45 females will be enrolled in 1 of 3 arms where they will receive either 125 mg PrimaVie, 250 mg PrimaVie or placebo (control) to take twice daily for 14 weeks.
Interventions
- DRUG Placebo
- DIETARY_SUPPLEMENT PrimaVie Herbal Supplement 125
- DIETARY_SUPPLEMENT PrimaVie Herbal Supplement 250
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2016-02-20 |
| Est. Completion | 2019-12-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02762032
The ClinicalTrials.gov registry entry for NCT02762032 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02762032 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02762032 about?
NCT02762032 is a clinical study titled "Natreon Healthy Skin Study - PrimaVie Supplement". This study will demonstrate the ability of the oral supplement, PrimaVie® to improve skin microperfusion, hydration, elasticity and barrier function. 45 females will be enrolled in 1 of 3 arms where they will receive either 125 mg PrimaVie, 250 mg PrimaVie or placebo (control) to take twice daily fo...
What is the current status of trial NCT02762032?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2016-02-20. Estimated completion is 2019-12-20.
What interventions are being tested in trial NCT02762032?
The interventions under investigation include: Placebo (DRUG), PrimaVie Herbal Supplement 125 (DIETARY_SUPPLEMENT), PrimaVie Herbal Supplement 250 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02762032?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.